systhiperСистемные гипертензииSystemic Hypertension2075-082X2542-2189LLC «ИнтерМедсервис»systhiper-130Research ArticleСТАТЬИARTICLESЭффективность и переносимость препарата Тарка у больных артериальной гипертензией (программа ТАНДЕМ)ЧазоваИ. Е.noemail@neicon.ruРатоваЛ. Г.noemail@neicon.ruФГУ РКНПК Росмедтехнологий, МоскваRussian Federation200823122022521617Copyright © Чазова И.Е., Ратова Л.Г., 20222022Чазова И.Е., Ратова Л.Г.Чазова И.Е., Ратова Л.Г.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.syst-hypertension.ru/jour/article/view/130ReferencesЧазова И.Е., Ратова Л.Г. Комбинированная терапия артериальной гипертонии. М.: Медиа Медика, 2007.Чазова И.Е., Ратова Л.Г. Комбинированная терапия артериальной гипертонии. М.: Медиа Медика, 2007.Kannel WB, Schwartz MJ, McNamara PM. Blood pressure and risk of coronary heart disease: the Framingham study. Dis Chest 1969; 56 (1): 43-52.Kannel WB, Schwartz MJ, McNamara PM. Blood pressure and risk of coronary heart disease: the Framingham study. Dis Chest 1969; 56 (1): 43-52.Stamler J, Neaton JD, Wentworth DN. Blood pressure (systolic and diastolic) and risk of fatal coronary heart disease. Hypertension 1989; 13 (5 Suppl.): I2.Stamler J, Neaton JD, Wentworth DN. Blood pressure (systolic and diastolic) and risk of fatal coronary heart disease. Hypertension 1989; 13 (5 Suppl.): I2.Miura K, Daviglus ML, Dyer AR et al. Relationship of blood pressure to 25-year mortality due to coronary heart disease, cardiovascular diseases, and all causes in young adult men: the Chicago Heart Association Detection Project in Industry. Arch Intern Med 2001; 161 (12): 1501-8.Miura K, Daviglus ML, Dyer AR et al. Relationship of blood pressure to 25-year mortality due to coronary heart disease, cardiovascular diseases, and all causes in young adult men: the Chicago Heart Association Detection Project in Industry. Arch Intern Med 2001; 161 (12): 1501-8.Lewington S, Clarke R, Qizilbash N et al. Prospective studies collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360 (9349): 1903-13.Lewington S, Clarke R, Qizilbash N et al. Prospective studies collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360 (9349): 1903-13.Coldberg AI, Dunlay MC, Sweet CS. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonists, compared with hydrochlorthiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibirors for the treatment of systemic hypertension. Am J Cardiol 1995; 75: 793-5.Coldberg AI, Dunlay MC, Sweet CS. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonists, compared with hydrochlorthiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibirors for the treatment of systemic hypertension. Am J Cardiol 1995; 75: 793-5.Tatti P, Pahor M, Buington R et al. Outcome results of the Fosinipril versus Amlodipine Cardiovascular events randomized trial (FACET) in patients with hypertension and NDDM. Diabetes Care 1998; 21: 579-603.Tatti P, Pahor M, Buington R et al. Outcome results of the Fosinipril versus Amlodipine Cardiovascular events randomized trial (FACET) in patients with hypertension and NDDM. Diabetes Care 1998; 21: 579-603.Elliott HL, Meredith PA. Clinical implications of the trough-peak ratio. Blood pressure Monit 1996; 6 (suppl. 1): 47-51.Elliott HL, Meredith PA. Clinical implications of the trough-peak ratio. Blood pressure Monit 1996; 6 (suppl. 1): 47-51.Holzgreve H. Safety profile of the combination of verapamil and trandolapril. J Hypertens Suppl 1997; 15 (2): 51-3.Holzgreve H. Safety profile of the combination of verapamil and trandolapril. J Hypertens Suppl 1997; 15 (2): 51-3.Staessen JA, Bieniaszewski L, O'Brien ET et al. An epidemiological approach to ambulatory blood pressure monitoring: the Belgian population study. Blood Pres Monitor 1996; 1: 13-26.Staessen JA, Bieniaszewski L, O'Brien ET et al. An epidemiological approach to ambulatory blood pressure monitoring: the Belgian population study. Blood Pres Monitor 1996; 1: 13-26.Johnston D, Lesoway R, Humen D, Kostuk W. Clinical and hemodynamic evaluation of propranolol in combination with verapamil, nifedipine and diltiazem in exertional angina pectoris: a placebo-controlled, double-blind, randomized, cross-over study. Am J Cardiol 1985; 55: 680-7.Johnston D, Lesoway R, Humen D, Kostuk W. Clinical and hemodynamic evaluation of propranolol in combination with verapamil, nifedipine and diltiazem in exertional angina pectoris: a placebo-controlled, double-blind, randomized, cross-over study. Am J Cardiol 1985; 55: 680-7.Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risks. US population data. Arch Intern Med 1993; 153 (5): 598-615.Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risks. US population data. Arch Intern Med 1993; 153 (5): 598-615.Fernandez R., Puig JG, Rodriguez-Perez JC et al. Effect of two antihypertensive combinations on metabolic control in type-2 diabetic hypertensive patients with albuminuria: a randomised, double-blind study. J Hum Hypertens 2001; 15: 849-56.Fernandez R., Puig JG, Rodriguez-Perez JC et al. Effect of two antihypertensive combinations on metabolic control in type-2 diabetic hypertensive patients with albuminuria: a randomised, double-blind study. J Hum Hypertens 2001; 15: 849-56.Bakris G, Molitch M, Hewkin A et al. Differences in Glucose Tolerance Between Fixed-Dose Antihypertensive Drug Combinations in People With Metabolic Syndrome. Diabetes Care 2006; 29: 2592-7.Bakris G, Molitch M, Hewkin A et al. Differences in Glucose Tolerance Between Fixed-Dose Antihypertensive Drug Combinations in People With Metabolic Syndrome. Diabetes Care 2006; 29: 2592-7.
The authors declare that there are no conflicts of interest present.